ERS3388614
SAMEA5584389
Ctl1
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584389
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl1
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTNI
organism part
blood
sample name
E-MTAB-7910:Ctl1
scientific_name
Homo sapiens
ERS3388615
SAMEA5584390
Ctl2
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584390
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl2
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTNI
organism part
blood
sample name
E-MTAB-7910:Ctl2
scientific_name
Homo sapiens
ERS3388616
SAMEA5584391
Ctl3
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584391
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl3
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTNI
organism part
blood
sample name
E-MTAB-7910:Ctl3
scientific_name
Homo sapiens
ERS3388617
SAMEA5584392
Ctl4
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584392
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl4
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QENI
organism part
blood
sample name
E-MTAB-7910:Ctl4
scientific_name
Homo sapiens
ERS3388618
SAMEA5584393
Ctl5
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584393
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl5
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QENI
organism part
blood
sample name
E-MTAB-7910:Ctl5
scientific_name
Homo sapiens
ERS3388619
SAMEA5584394
Ctl6
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584394
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:Ctl6
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QENI
organism part
blood
sample name
E-MTAB-7910:Ctl6
scientific_name
Homo sapiens
ERS3388620
SAMEA5584395
QE1
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584395
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:QE1
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QEI
organism part
blood
sample name
E-MTAB-7910:QE1
scientific_name
Homo sapiens
ERS3388622
SAMEA5584397
QE3
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584397
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:QE3
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QEI
organism part
blood
sample name
E-MTAB-7910:QE3
scientific_name
Homo sapiens
ERS3388623
SAMEA5584398
WT1
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584398
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:WT1
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTI
organism part
blood
sample name
E-MTAB-7910:WT1
scientific_name
Homo sapiens
ERS3388624
SAMEA5584399
WT2
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584399
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:WT2
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTI
organism part
blood
sample name
E-MTAB-7910:WT2
scientific_name
Homo sapiens
ERS3388625
SAMEA5584400
WT3
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584400
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:WT3
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
WTI
organism part
blood
sample name
E-MTAB-7910:WT3
scientific_name
Homo sapiens
ERS3388621
SAMEA5584396
QE2
9606
Homo sapiens
Protocols: We used lentiviral pV81 vectors with doxycycline inducible expression of WT or mutant SPI1 fused to GFP (pV81/GFP-SPI1) and GFP alone. The pV81 backbone was described in this reference : Calvo J, BenYoucef A, Baijer J, Rouyez MC, Pflumio F. Assessment of human multipotent hematopoietic stem/progenitor cell potential using a single in vitro screening system. PLoS One. 2012;7:e50495. Tumor cells were defined by the positivity of CD19 and monotypic light chain (LC) while control samples were CD3-positive T lymphocytes. The cellular populations were sorted using an Influx cell sorter (BD Biosciences, San Jose, CA, USA). The sorted cells were subjected to an additional round of sorting to provide a cell fraction purity of more than 98% and subjected to DNA/RNA extraction using the AllPrep DNA/RNA Kit (Qiagen). Qiagen RNA-seq was performed as described in Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 2014;4(9):1088-101 doi 10.1158/2159-8290.
ENA-FIRST-PUBLIC
2019-05-10T04:03:01Z
ENA-LAST-UPDATE
2019-04-30T10:02:32Z
External Id
SAMEA5584396
INSDC center name
INSERM U1170, Gustave Roussy, Villejuif, France
INSDC first public
2019-05-10T04:03:01Z
INSDC last update
2019-04-30T10:02:32Z
INSDC status
public
Submitter Id
E-MTAB-7910:QE2
broker name
ArrayExpress
cell line
OCI-LY10
cell type
lymphoma B cell
common name
human
disease
diffuse large B-cell lymphoma
genotype
QEI
organism part
blood
sample name
E-MTAB-7910:QE2
scientific_name
Homo sapiens